Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)
Completed · Phase 1/Phase 2
Conditions studied: X-linked Retinoschisis
In brief
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector expressing retinoschisin (rAAV2tYF-CB-hRS1) in patients with X-linked retinoschisis. Up to 27 participants will be enrolled and 3 dose levels will be evaluated in a dose escalation format.
Key facts
- Study ID
- NCT02416622
- Run by
- Beacon Therapeutics
- People needed
- 27
- Starts
- 2015-05-01
- Expected to finish
- 2023-05-09
- Last updated by the study team
- 2023-06-12
Who can join
Age: 6 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- University of California San Francisco, Dept. of Ophthalmology — San Francisco, California, United States
- University of Miami - Miller School of Medicine Bascom Palmer Eye Institute — Miami, Florida, United States
- The Wilmer Eye Institute, Johns Hopkins Hospital — Baltimore, Maryland, United States
- Massachusetts Eye and Ear Infirmary — Boston, Massachusetts, United States
- University of Michigan Kellogg Eye Center — Ann Arbor, Michigan, United States
- Duke Eye Center, Duke University Medical Center — Durham, North Carolina, United States
- Casey Eye Institute, Oregon Health and Sciences University — Portland, Oregon, United States
- Retina Foundation of the Southwest — Dallas, Texas, United States
- Baylor College of Medicine, Alkek Eye Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.